Moderna reports first positive Phase 3 for mRNA neoantigen therapy in melanoma
Moderna reports first positive Phase 3 for mRNA neoantigen therapy in melanoma
Moderna 报告 mRNA 新抗原疗法在黑色素瘤治疗中首次取得三期临床积极成果
Noubar Afeyan: Today marks an important milestone for @moderna_tx, for the field of mRNA, and for the many people working to bring new possibilities to patients. This morning, Moderna and Merck announced positive Phase 3 results for adjuvant treatment with intismeran autogene, an individualized mRNA therapy for melanoma, in combination with KEYTRUDA, in patients with completely resected stage IIB-IV melanoma.
Noubar Afeyan： 今天对于 Moderna、对于 mRNA 领域，以及对于许多致力于为患者带来新可能的人们来说，是一个重要的里程碑。今天上午，Moderna 和默沙东（Merck）宣布，在完全切除的 IIB-IV 期黑色素瘤患者中，使用 intismeran autogene（一种针对黑色素瘤的个体化 mRNA 疗法）联合 KEYTRUDA 进行辅助治疗，取得了积极的三期临床试验结果。
The study met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival. This is the first positive Phase 3 result for an individualized neoantigen therapy, and the first for an mRNA-based cancer therapy.
该研究达到了无复发生存期的主要终点，以及无远处转移生存期的关键次要终点。这是个体化新抗原疗法首次取得三期临床积极结果，也是基于 mRNA 的癌症疗法首次取得此类成果。
When we founded Moderna in 2010, the idea that mRNA could become a new class of medicines was outright rejected. The idea that we might use it to create a therapy designed around the unique mutations in an individual patient’s tumor was even further from reality. Today’s result is a reminder of what can emerge from pioneering: asking questions others have not yet asked, following the science where it leads, and persevering through uncertainty.
2010 年我们创立 Moderna 时，mRNA 能成为一类新药的想法遭到了彻底的否定。而利用它来开发针对个体患者肿瘤独特突变的疗法，在当时更是遥不可及。今天的结果提醒我们，开拓创新意味着什么：提出他人尚未提出的问题，追随科学的指引，并在不确定性中坚持不懈。
There is important work still ahead but today is a moment to recognize the extraordinary work behind this milestone. Congratulations to the entire Moderna team, our partners at Merck, and the investigators who made this study possible. Most importantly, my gratitude goes to the patients and families whose participation enables progress like this. Proud of this milestone, and of everyone who helped bring us here.
未来仍有重要的工作要做，但今天是一个值得认可这一里程碑背后非凡工作的时刻。祝贺整个 Moderna 团队、我们的合作伙伴默沙东，以及使这项研究成为可能的研究人员。最重要的是，我向参与其中的患者及其家属表示感谢，是你们的参与促成了这样的进步。为这一里程碑感到自豪，也为每一位帮助我们走到今天的人感到骄傲。
Moderna: Moderna and @Merck today announced positive topline results from the Phase 3 INTerpath-001 trial evaluating adjuvant treatment with intismeran autogene, a novel investigational mRNA-based individualized neoantigen therapy jointly developed by Merck and Moderna, in combination.
Moderna： Moderna 和默沙东今天宣布了 INTerpath-001 三期临床试验的积极顶线结果。该试验评估了 intismeran autogene 的辅助治疗效果，这是一种由默沙东和 Moderna 联合开发的新型在研 mRNA 个体化新抗原疗法。
Ash Vardanian: Congratulations! Small step for Moderna - huge step for humanity ;)
Ash Vardanian： 恭喜！这是 Moderna 的一小步，却是人类的一大步 ;)
T: I’m against vaccines for a lot of things, but if it’s being used to treat cancer and someone is going to pass either way, then side effects 10+ years down the road don’t really matter if it can give them more time to enjoy life. Hopefully, this can work for all types of cancer.
T： 我反对很多疫苗，但如果它是用来治疗癌症，且患者无论如何都可能面临生命危险，那么如果它能让人多活几年去享受生活，10 年后的副作用其实并不重要。希望这种疗法能适用于所有类型的癌症。
Anant Sundaram: Kudos to you and the team that led this!
Anant Sundaram： 向你和领导这项研究的团队致敬！